NextCure, Inc.
NXTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001661059
In the last 90 days, NextCure, Inc. insiders filed 2 open-market purchases and 1 sale; 30 institutions reported holding it in 13F filings for Q2 2026, worth $2.78M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding NextCure, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 52 | 45 | −7 |
| Shares | 15.2M | 13.4M | −1.85M (−12.2%) |
| Value | $41.8M | $18.9M | −$22.9M (−54.8%) |
New holders (6)
Institutions that held NextCure, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cardiff Park Advisors, LLC | 262,000 | $369.4K | 0.05% |
| Susquehanna International Group, LLP | 47,957 | $67.6K | 0.00% |
| Jane Street Group, LLC | 23,742 | $33.5K | 0.00% |
| Virtu Financial LLC | 19,580 | $28.0K | 0.00% |
| Ergoteles LLC | 17,576 | $24.8K | 0.00% |
| D. E. Shaw & Co., Inc. | 13,860 | $19.5K | 0.00% |
Sold out (13)
Institutions that held NextCure, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| K2 Principal Fund, L.P. | 1,581,311 | $4.19M |
| Connor, Clark & Lunn Investment Management Ltd. | 95,888 | $264.0K |
| Nomura Holdings Inc | 51,910 | $148.0K |
| FNY Investment Advisers, LLC | 48,000 | $132.0K |
| Krensavage Asset Management, LLC | 31,298 | $86.0K |
| Group One Trading, L.P. | 30,093 | $83.0K |
| Privium Fund Management (UK) Ltd | 24,400 | $67.0K |
| Algert Global LLC | 22,872 | $63.0K |
| Cubist Systematic Strategies, LLC | 12,163 | $33.0K |
| Citigroup Inc | 327 | $1.00K |
| China Universal Asset Management Co., Ltd. | 260 | $1.00K |
| Royal Bank of Canada | 169 | $0 |
| Daiwa Securities Group Inc. | 52 | $0 |